Johnson & Johnson Opioid Settlement May Provide $5B For States and Cities Nationwide
Johnson & Johnson has announced it is increasing its opioid crisis settlement commitment to $5 billion.
Johnson & Johnson has announced it is increasing its opioid crisis settlement commitment to $5 billion.
A new study suggests taking antibiotics along with opioids may increase the risks of drug addiction.
Plaintiffs involved in opioid crisis lawsuits have proposed a settlement negotiation structure which would involve every city and county within the United States.
The U.S. JPML has refused to create a separate multidistrict litigation for lawsuits over children suffering from neonatal abstinence syndrome caused by opioids.
Manufacturers of opioids say they oppose the creation of a separate federal consolidated litigation for cases involving infants born addicted to opioids.
Plaintiffs say that lawsuits against drug manufacturers brought by children born with opioid dependency should have their own consolidated pretrial proceedings.
Bellwether trials will likely be needed before opioid settlement agreements can be reached, according to the federal judge overseeing the multidistrict litigation.
A new study finds varying prescribing patterns for opioids which result in thousands of unused pills that could be feeding the nationwide opioid abuse crisis.
A conference is scheduled next week to begin preliminary settlement discussions on opioid lawsuits filed against drug manufacturers by communities and states nationwide.
An Australian study indicates that tamper-resistant pill designs did little to stave off or deter the opioid abuse crisis.